Opening question: When a research-peptide catalog flashes “TraML,” an SRM/MRM transition list, or “targeted peptide assay file format” next to a vial SKU, how do you tell HUPO PSI transition-list literacy from proof that the peptide is cleared for people?
Short answer: open the HUPO PSI TraML page and keep it distinct from mzML (spectra) and mzIdentML (identification results). The HUPO PSI Mass Spectrometry Standards Working Group developed TraML as a standardized format for the exchange and transmission of transition lists for selected reaction monitoring (SRM) experiments. TraML 1.0.0 completed the PSI document process and was released as a finished specification. That is targeted-assay exchange infrastructure. It is not a drug-approval system, and a TraML screenshot next to a research peptide does not mean the SKU was authorized as a medicine.
A practical TraML checklist when ads lean on transition-list badges:
- What a transition list is: In SRM/MRM workflows, laboratories exchange precursor/product ion transitions and related method parameters so instruments can target specific peptides. TraML standardizes that exchange. Targeted measurement methods are laboratory practice—not human-use clearance for a catalog chemical.
- Finished PSI specification, not a pharmacy dossier: The TraML page documents schema (TraML1.0.0.xsd), a full specification PDF, HTML schema docs, controlled-vocabulary mapping, and sample instance documents. Completing the PSI process means peer standards review for interoperability. It does not evaluate a seller’s research peptide as medicine.
- Distinct from mzML / mzIdentML / USI: mzML carries spectrum data; mzIdentML carries identification results; Universal Spectrum Identifiers cite spectra in repositories. TraML answers a different need: portable SRM transition lists. Do not collapse any of those badges into product approval.
- Citation and examples are for implementers: The page asks readers to cite Deutsch et al., 2011 (MCP) when referencing TraML and points to example TraML files. That helps software and method sharing. It is still not a clinical label for a vial.
- What to open next: If an ad claims “SRM-validated” or shows a TraML tree beside a SKU, open the PSI TraML page, note whether a public assay method is actually cited, and separate method-file literacy from medical authorization.
None of those steps turns a laboratory research listing into an approved medicine. Company research-only catalogs document laboratory intent and paperwork such as certificates of analysis; they do not create human-use approval. For company facts only—not clinical evidence—Apollo Peptides states products are for laboratory research only, not for human or veterinary use, and describes third-party testing with certificates of analysis.
Bottom line: Use TraML to understand how targeted MS transition lists are standardized for exchange, then ask whether the ad is teaching that distinction or implying a research peptide is medically meaningful because an SRM-format badge looks official. That habit changes what you notice in catalogs—it is not advice to buy, inject, or dose any peptide.
By The Everyday Brief · AI-assisted editorial. Drafted with AI research assistance; claims checked against the HUPO PSI TraML page (fetched 2026-09-29 PT). No invented studies, quotes, or dosing. Not medical or legal advice.
Sources
4. Apollo Peptides (company facts only)
Related reading
What mzML Means When Peptide Ads Flash Mass-Spectrometry File-Format Badges
What Universal Spectrum Identifiers Mean When Peptide Ads Flash Spectrum Strings
What PeptideAtlas means when ads say MS-confirmed or proteomics-validated